University of Limerick Institutional Repository

Anti-microbial coating innovations to prevent infectious diseases (AMiCI): cost action ca15114

DSpace Repository

Show simple item record

dc.contributor.author Dunne, Colum P.
dc.contributor.author Keinänen-Toivola, Minna M.
dc.contributor.author Kahru, Anne
dc.contributor.author Teunissen, Birgit
dc.contributor.author Olmez, Hulya
dc.contributor.author Gouveia, Isabel
dc.contributor.author Melo, Luis
dc.contributor.author Murzyn, Kazimierz
dc.contributor.author Modic, Martina
dc.contributor.author Ahonen, Merja
dc.contributor.author Askew, Pete
dc.contributor.author Papadopoulos, Theofilos
dc.contributor.author Adlhart, Christian
dc.contributor.author Crijns, Francy R.L.
dc.date.accessioned 2018-02-08T10:34:10Z
dc.date.available 2018-02-08T10:34:10Z
dc.date.issued 2017
dc.identifier.uri http://hdl.handle.net/10344/6535
dc.description peer-reviewed en_US
dc.description.abstract Worldwide, millions of patients are affected annually by healthcare-associated infection (HCAI), impacting up to 80,000 patients in European Hospitals on any given day. This represents not only public health risk, but also an economic burden. Complementing routine hand hygiene practices, cleaning and disinfection, antimicrobial coatings hold promise based, in essence, on the application of materials and chemicals with persistent bactericidal or static properties onto surfaces or in textiles used in healthcare environments. The focus of considerable commercial investment and academic research energies, such antimicrobial coating-based approaches are widely believed to have potential in reduction of microbial numbers on surfaces in clinical settings. This belief exists despite definitive evidence as to their efficacy and is based somewhat on positive studies involving, for example, copper, silver or gold ions, titanium or organosilane, albeit under laboratory conditions. The literature describes successful delay and/or prevention of recontamination following conventional cleaning and disinfection by problematic microbes such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococci (VRE), among others. However, there is a scarcity of studies assessing antimicrobial surfaces other than copper in the clinical environment, and a complete lack of published data regarding the successful implementation of these materials on clinically significant outcomes (including HCAI). Through its Cooperation in Science and Technology program (COST), the European Commission has funded a 4-year initiative to establish a network of stakeholders involved in development, regulation and use of novel anti-microbial coatings for prevention of HCAI. The network (AMiCI) comprises participants of more than 60 universities, research institutes and companies across 29 European countries and, to-date, represents the most comprehensive consortium targeting use of these emergent technologies in healthcare settings. More specifically, the network will prioritise coordinated research on the effects (both positive and negative) of antimicrobial coatings in healthcare sectors; know-how regarding availability and mechanisms of action of (nano)-coatings; possible adverse effects of such materials (e.g., potential emergence of microbial resistance or emission of toxic agents into the environment); standardised performance assessments for antimicrobial coatings; identification and dissemination of best practices by hospitals, other clinical facilities, regulators and manufacturers. en_US
dc.language.iso eng en_US
dc.publisher Taylor & Francis en_US
dc.relation.ispartofseries Bioengineered;8 (6), pp. 679-685
dc.relation.uri https://doi.org/10.1080/21655979.2017.1323593
dc.subject acquired en_US
dc.subject antimicrobial en_US
dc.subject antibacterial en_US
dc.subject coatings en_US
dc.subject COST en_US
dc.subject healthcare en_US
dc.subject hospital en_US
dc.subject infection en_US
dc.subject prevention en_US
dc.subject risk benefit analysis en_US
dc.title Anti-microbial coating innovations to prevent infectious diseases (AMiCI): cost action ca15114 en_US
dc.type info:eu-repo/semantics/article en_US
dc.type.supercollection all_ul_research en_US
dc.type.supercollection ul_published_reviewed en_US
dc.identifier.doi 10.1080/21655979.2017.1323593
dc.contributor.sponsor COST Action AMiCI en_US
dc.contributor.sponsor COST (European Cooperation in Science and Technology) en_US
dc.relation.projectid CA15114 en_US
dc.rights.accessrights info:eu-repo/semantics/openAccess en_US
dc.internal.rssid 2708255


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ULIR


Browse

My Account

Statistics